von Willebrand Factor antibody | RFF-VIII R/2
Mouse anti Human von Willebrand Factor antibody, clone RFF-VIII R/2 (MCA4683) used as a blocking antibody in an ELISA to assess binding of vWF to immobilized MMRN1.
Image caption:
Binding of WT-VWF and VWF mutant proteins to immobilized MMRN1, with or without inhibitors. A) The binding of 0.5 μg/ml shear-exposed WT-VWF, and VWF mutant proteins lacking all or one A domain (ΔA1A2A3, ΔA1, ΔA2, ΔA3), to MMRN1. * indicate reduced binding (p <0.01), relative to WT-VWF. B) Effect of MCA4683 (2 μg/ml, a VWF A1 domain antibody that inhibits GPIbα binding) or negative control mIgG (2 μg/ml) on VWF-MMRN1 binding in the presence of ristocetin. * indicates reduced (p <0.05), relative to WT-VWF with no inhibitor. C) Effect of RU5 (2 μg/ml, a VWF A3 domain antibody that inhibits collagen binding) and mIgG (2 μg/ml; negative control) on VWF-MMRN1 binding. * indicates reduced (p <0.05), relative to WT-VWF with no inhibitor. D) Effect of type III collagen peptides that bind to VWF A3 domain (III-23: GPOGPSGPRGQOGVMGFOGPKGNDGAO, and GPRGQOGVMGFO) and the negative control peptide, GPP, on VWF-MMRN1 binding. * indicates reduced, (p <0.05), relative to WT-VWF with no inhibitor. WT-VWF binding (1 μg/ml) to immobilised MMRN1 was measured following simultaneous addition of VWF and an antibody or peptide. Panels show representative (D) or pooled (A-C) data for three separate independent experiments, expressed as the mean OD 450 nm ± SEM.
From: Parker DN, Tasneem S, Farndale RW, Bihan D, Sadler JE, Sebastian S, de Groot PG, Hayward CP.
The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding.
Thromb Haemost. 2016 Jul 4;116(1):87-95.
doi: 10.1160/TH15-09-0700.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Mouse anti Human von Willebrand Factor antibody, clone RFF-VIII R/2 (MCA4683) used as a blocking antibody in an in vitro assay to assess binding of vWF to immobilized MMRN1.
Image caption:
Effect of inhibitory antibodies on the ability of VWF to support high shear platelet adhesion to immobilised MMRN1. Bars show mean ± SEM for the percentage of the surface area [%] covered by platelets for the adhesion of control platelets (300 × 106/ml) to immobilised MMRN1, tested at a shear rate of 1500 s-1 after pre-treatment with: WT-VWF (40 nM, positive control); WT-VWF + MCA4683 (20 μg/ml, inhibits VWF-GPIbα binding); BSA (negative control); or WT-VWF + mIgG (20 pg/ml, negative control). Reduced platelet adhesion to MMRN1 is indicated (*; p <0.001, relative to MMRN1 pre-treated with WT-VWF only; data representative of two independent experiments).
From: Parker DN, Tasneem S, Farndale RW, Bihan D, Sadler JE, Sebastian S, de Groot PG, Hayward CP.
The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding.
Thromb Haemost. 2016 Jul 4;116(1):87-95.
doi: 10.1160/TH15-09-0700.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Mouse anti Human von Willebrand Factor antibody, clone RFF-VIII R/2 recognizes human von Willebrand factor (vWF), also known as Factor VIII related antigen, a blood glycoprotein involved in blood coagulation. It stabilises circulating Factor VIII by binding to it and protecting it from cleavage and delivers it to sites of vascular injury. vWF also promotes the adhesion of platelets to sites of vascular damage by forming a molecular bridge between collagen on exposed endothelial cells and the GPIb binding sites of platelets circulating in the blood. vWF circulates in the blood as large multimers, with each monomer (250 kDa) containing a number of specific domains.
Hereditary or acquired defects in vWF lead to von Willebrand disease (vWD), characterised by varying degrees of susceptibility to bleeding. Symptoms might include nosebleeds, bleeding gums, easy bruising, menorrrhagia or gastrointestinal bleeding. Various forms of vWD exist with differing severities, determined by the type of defect.
Clone RF-VIII R/2 has a high affinity for an epitope within the platelet GPIb-binding site that is responsible for biological activity. As such the antibody is a potent inhibitor of vWF activity. It can completely neutralise ristocetin-induced platelet aggregation, platelet binding to the subendothelium and ristocetin-induced binding of vWF to platelets. It also inhibits platelet adhesion to glass beads. The epitope recognized is present only on the intact multimeric form of vWF and is abolished by mild denaturation with SDS. The antibody does not recognize human Factor VIII.
Mouse anti Human von Willebrand Factor antibody, clone RFF-VIII R/2 may be used to detect vWF in immunoassays in combination with clone Mouse anti Human von Willebrand Factor antibody, clone RFF-VIII R/1 (MCA4682) as a capture reagent.
Hereditary or acquired defects in vWF lead to von Willebrand disease (vWD), characterised by varying degrees of susceptibility to bleeding. Symptoms might include nosebleeds, bleeding gums, easy bruising, menorrrhagia or gastrointestinal bleeding. Various forms of vWD exist with differing severities, determined by the type of defect.
Clone RF-VIII R/2 has a high affinity for an epitope within the platelet GPIb-binding site that is responsible for biological activity. As such the antibody is a potent inhibitor of vWF activity. It can completely neutralise ristocetin-induced platelet aggregation, platelet binding to the subendothelium and ristocetin-induced binding of vWF to platelets. It also inhibits platelet adhesion to glass beads. The epitope recognized is present only on the intact multimeric form of vWF and is abolished by mild denaturation with SDS. The antibody does not recognize human Factor VIII.
Mouse anti Human von Willebrand Factor antibody, clone RFF-VIII R/2 may be used to detect vWF in immunoassays in combination with clone Mouse anti Human von Willebrand Factor antibody, clone RFF-VIII R/1 (MCA4682) as a capture reagent.
Product Details
- Target Species
- Human
- Product Form
- Purified IgG - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Carrier Free
- Yes
- Immunogen
- Human Factor VIII complex partially purified from Factor VIII concentrate.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
Storage Information
- Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. - Guarantee
- 12 months from date of despatch
More Information
- UniProt
- P04275
- Entrez Gene
- VWF
- GO Terms
- GO:0001948 glycoprotein binding
- GO:0002020 protease binding
- GO:0002576 platelet degranulation
- GO:0051087 chaperone binding
- GO:0005783 endoplasmic reticulum
- GO:0005178 integrin binding
- GO:0005518 collagen binding
- GO:0005578 proteinaceous extracellular matrix
- GO:0007597 blood coagulation, intrinsic pathway
- GO:0019865 immunoglobulin binding
- GO:0030168 platelet activation
- GO:0031093 platelet alpha granule lumen
- GO:0031589 cell-substrate adhesion
- GO:0033093 Weibel-Palade body
- GO:0042803 protein homodimerization activity
- GO:0051260 protein homooligomerization
- GO:0047485 protein N-terminus binding
- Regulatory
- For research purposes only
Applications of von Willebrand Factor antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| Immunohistology - Frozen 1 | 1/25 | 1/100 | |
| Immunohistology - Paraffin | |||
| Protein Purification | |||
| Radioimmunoassays | |||
| Western Blotting |
- 1The epitope recognised by this antibody is reported to be sensitive to formaldehyde fixation and tissue processing. Bio-Rad recommends the use of acetone fixation for frozen sections.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Histology Positive Control Tissue
- Human tonsil, thymus, liver, spleen or kidney.
Copyright © 2021 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Product Specific References
References for von Willebrand Factor antibody
-
Goodall, A.H. et al. (1985) An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope.
Br J Haematol. 59 (4): 565-77. -
Goodall, A.H. & Meyer, D. (1985) Registry of monoclonal antibodies to factor VIII and von Willebrand factor. International Committee on Thrombosis and Haemostasis.
Thromb Haemost. 54 (4): 878-91. -
Chand, S. et al. (1986) A two-site, monoclonal antibody-based immunoassay for von Willebrand factor--demonstration that vWF function resides in a conformational epitope.
Thromb Haemost. 55 (3): 318-24. -
Parker, D.N. et al. (2016) The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding.
Thromb Haemost. 116 (1): 87-95.
Fluorescent Spectraviewer
Watch the Tool Tutorial Video ▸How to Use the Spectraviewer
Watch the Tool Tutorial Video ▸- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
